Extensions for Using Data Elements from FHIR R4 in FHIR R5
0.1.0 - STU
Extensions for Using Data Elements from FHIR R4 in FHIR R5
0.1.0 - STU
Extensions for Using Data Elements from FHIR R4 in FHIR R5 - Downloaded Version null See the Directory of published versions
| Page standards status: External | Maturity Level: 0 |
<CodeSystem xmlns="http://hl7.org/fhir">
<id value="v3-substanceAdminSubstitution"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: CodeSystem v3-substanceAdminSubstitution</b></p><a name="v3-substanceAdminSubstitution"> </a><a name="hcv3-substanceAdminSubstitution"> </a><p><b>Properties</b></p><p><b>This code system defines the following properties for its concepts</b></p><table class="grid"><tr><td><b>Name</b></td><td><b>Code</b></td><td><b>URI</b></td><td><b>Type</b></td><td><b>Description</b></td></tr><tr><td>Not Selectable</td><td>notSelectable</td><td>http://hl7.org/fhir/concept-properties#notSelectable</td><td>boolean</td><td>Indicates that the code is abstract - only intended to be used as a selector for other concepts</td></tr></table><p><b>Concepts</b></p><p>This case-sensitive code system <code>http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution</code> defines the following codes in a Is-A hierarchy:</p><table class="codes"><tr><td><b>Lvl</b></td><td style="white-space:nowrap"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td><td><b>Not Selectable</b></td></tr><tr><td>1</td><td style="white-space:nowrap">_ActSubstanceAdminSubstitutionCode<a name="v3-substanceAdminSubstitution-_ActSubstanceAdminSubstitutionCode"> </a></td><td>ActSubstanceAdminSubstitutionCode</td><td><div><p>Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects.</p>
</div></td><td>true</td></tr><tr><td>2</td><td style="white-space:nowrap"> E<a name="v3-substanceAdminSubstitution-E"> </a></td><td>equivalent</td><td><div><p>Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product.</p>
</div></td><td/></tr><tr><td>3</td><td style="white-space:nowrap"> EC<a name="v3-substanceAdminSubstitution-EC"> </a></td><td>equivalent composition</td><td><div><p>Description:</p>
<pre><code> Substitution occurred or is permitted with another product that is a:
pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester
pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration
Examples:
Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate
Pharmaceutical equivalent: Lisonpril for Zestril
</code></pre>
</div></td><td/></tr><tr><td>4</td><td style="white-space:nowrap"> BC<a name="v3-substanceAdminSubstitution-BC"> </a></td><td>brand composition</td><td><div><p>Description:</p>
<pre><code> Substitution occurred or is permitted between equivalent Brands but not Generics
Examples:
Zestril for Prinivil
Coumadin for Jantoven
</code></pre>
</div></td><td/></tr><tr><td>4</td><td style="white-space:nowrap"> G<a name="v3-substanceAdminSubstitution-G"> </a></td><td>generic composition</td><td><div><p>Description: Substitution occurred or is permitted between equivalent Generics but not Brands</p>
<pre><code> Examples:
Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)
</code></pre>
</div></td><td/></tr><tr><td>3</td><td style="white-space:nowrap"> TE<a name="v3-substanceAdminSubstitution-TE"> </a></td><td>therapeutic alternative</td><td><div><p>Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile.</p>
<pre><code> Examples:
ranitidine for Tagamet
</code></pre>
</div></td><td/></tr><tr><td>4</td><td style="white-space:nowrap"> TB<a name="v3-substanceAdminSubstitution-TB"> </a></td><td>therapeutic brand</td><td><div><p>Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics</p>
<blockquote>
</blockquote>
<pre><code> Examples:
Zantac for Tagamet
</code></pre>
</div></td><td/></tr><tr><td>4</td><td style="white-space:nowrap"> TG<a name="v3-substanceAdminSubstitution-TG"> </a></td><td>therapeutic generic</td><td><div><p>Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands</p>
<blockquote>
</blockquote>
<pre><code> Examples:
Ranitidine for cimetidine
</code></pre>
</div></td><td/></tr><tr><td>2</td><td style="white-space:nowrap"> F<a name="v3-substanceAdminSubstitution-F"> </a></td><td>formulary</td><td><div><p>Description: This substitution was performed or is permitted based on formulary guidelines.</p>
</div></td><td/></tr><tr><td>2</td><td style="white-space:nowrap"> N<a name="v3-substanceAdminSubstitution-N"> </a></td><td>none</td><td><div><p>No substitution occurred or is permitted.</p>
</div></td><td/></tr></table></div>
</text>
<extension
url="http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status">
<valueCode value="external"/>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm">
<valueInteger value="0"/>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/package-source">
<extension url="packageId">
<valueId value="hl7.fhir.uv.xver-r4.r5"/>
</extension>
<extension url="version">
<valueString value="0.1.0"/>
</extension>
<extension url="uri">
<valueUri
value="http://hl7.org/fhir/uv/xver/ImplementationGuide/hl7.fhir.uv.xver-r4.r5"/>
</extension>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/structuredefinition-wg">
<valueCode value="fhir"/>
</extension>
<url
value="http://terminology.hl7.org/CodeSystem/v3-substanceAdminSubstitution"/>
<version value="2018-08-12"/>
<name value="v3.substanceAdminSubstitution"/>
<title value="v3 Code System substanceAdminSubstitution"/>
<status value="active"/>
<experimental value="false"/>
<date value="2018-08-11T09:00:00-05:00"/>
<publisher value="FHIR Infrastructure"/>
<contact>
<name value="FHIR Infrastructure"/>
<telecom>
<system value="url"/>
<value value="http://www.hl7.org/Special/committees/fiwg"/>
</telecom>
</contact>
<description
value="Identifies what sort of change is permitted or has occurred between the therapy that was ordered and the therapy that was/will be provided."/>
<jurisdiction>
<coding>
<system value="http://unstats.un.org/unsd/methods/m49/m49.htm"/>
<code value="001"/>
<display value="World"/>
</coding>
</jurisdiction>
<caseSensitive value="true"/>
<valueSet
value="http://terminology.hl7.org/ValueSet/v3-substanceAdminSubstitution"/>
<hierarchyMeaning value="is-a"/>
<content value="complete"/>
<property>
<code value="notSelectable"/>
<uri value="http://hl7.org/fhir/concept-properties#notSelectable"/>
<description
value="Indicates that the code is abstract - only intended to be used as a selector for other concepts"/>
<type value="boolean"/>
</property>
<concept>
<code value="_ActSubstanceAdminSubstitutionCode"/>
<display value="ActSubstanceAdminSubstitutionCode"/>
<definition
value="Description: Substitution occurred or is permitted with another product that may potentially have different ingredients, but having the same biological and therapeutic effects."/>
<property>
<code value="notSelectable"/>
<valueBoolean value="true"/>
</property>
<concept>
<code value="E"/>
<display value="equivalent"/>
<definition
value="Description: Substitution occurred or is permitted with another bioequivalent and therapeutically equivalent product."/>
<concept>
<code value="EC"/>
<display value="equivalent composition"/>
<definition
value="Description:
Substitution occurred or is permitted with another product that is a:
pharmaceutical alternative containing the same active ingredient but is formulated with different salt, ester
pharmaceutical equivalent that has the same active ingredient, strength, dosage form and route of administration
Examples:
Pharmaceutical alternative: Erythromycin Ethylsuccinate for Erythromycin Stearate
Pharmaceutical equivalent: Lisonpril for Zestril"/>
<concept>
<code value="BC"/>
<display value="brand composition"/>
<definition
value="Description:
Substitution occurred or is permitted between equivalent Brands but not Generics
Examples:
Zestril for Prinivil
Coumadin for Jantoven"/>
</concept>
<concept>
<code value="G"/>
<display value="generic composition"/>
<definition
value="Description: Substitution occurred or is permitted between equivalent Generics but not Brands
Examples:
Lisnopril (Lupin Corp) for Lisnopril (Wockhardt Corp)"/>
</concept>
</concept>
<concept>
<code value="TE"/>
<display value="therapeutic alternative"/>
<definition
value="Description: Substitution occurred or is permitted with another product having the same therapeutic objective and safety profile.
Examples:
ranitidine for Tagamet"/>
<concept>
<code value="TB"/>
<display value="therapeutic brand"/>
<definition
value="Description: Substitution occurred or is permitted between therapeutically equivalent Brands but not Generics
>
Examples:
Zantac for Tagamet"/>
</concept>
<concept>
<code value="TG"/>
<display value="therapeutic generic"/>
<definition
value="Description: Substitution occurred or is permitted between therapeutically equivalent Generics but not Brands
>
Examples:
Ranitidine for cimetidine"/>
</concept>
</concept>
</concept>
<concept>
<code value="F"/>
<display value="formulary"/>
<definition
value="Description: This substitution was performed or is permitted based on formulary guidelines."/>
</concept>
<concept>
<code value="N"/>
<display value="none"/>
<definition value="No substitution occurred or is permitted."/>
</concept>
</concept>
</CodeSystem>
IG © 2025+ FHIR Infrastructure. Package hl7.fhir.uv.xver-r4.r5#0.1.0 based on FHIR 5.0.0. Generated 2026-03-20
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change